Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
38.5M
-
Number of holders
-
36
-
Total 13F shares, excl. options
-
6.87M
-
Shares change
-
+569K
-
Total reported value, excl. options
-
$46.5M
-
Value change
-
+$3.84M
-
Number of buys
-
19
-
Number of sells
-
-13
-
Price
-
$6.75
Significant Holders of Protara Therapeutics, Inc. - Common Stock (TARA) as of Q4 2021
41 filings reported holding TARA - Protara Therapeutics, Inc. - Common Stock as of Q4 2021.
Protara Therapeutics, Inc. - Common Stock (TARA) has 36 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6.87M shares
of 38.5M outstanding shares and own 17.87% of the company stock.
Largest 10 shareholders include Opaleye Management Inc. (2.65M shares), ORBIMED ADVISORS LLC (831K shares), VANGUARD GROUP INC (435K shares), CITADEL ADVISORS LLC (428K shares), PERCEPTIVE ADVISORS LLC (422K shares), Ikarian Capital, LLC (279K shares), DLD Asset Management, LP (229K shares), BOXER CAPITAL, LLC (209K shares), BAKER BROS. ADVISORS LP (200K shares), and GOLDMAN SACHS GROUP INC (197K shares).
This table shows the top 36 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.